Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA

European Journal of Human Genetics

Volumn 22, Issue 9, 2014, Pages 1085-1092

  Bordeira Carriço, Renata ^a   Ferreira, Daniel ^a   Mateus, Denisa D ^a   Pinheiro, Hugo ^a   Pêgo, Ana Paula ^a,b   Santos, Manuel A S ^c   Oliveira, Carla ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

hereditary diffuse gastric cancer (HDGC); nonsense suppression; premature termination codon (PTC); suppressor tRNA

Indexed keywords

AMINO ACID; ARGININE; DNA; MESSENGER RNA; RNA; TRANSFER RNA; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; STOP CODON; ARGININE TRANSFER RNA; SUPPRESSOR ARGININE TRANSFER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; NONSENSE MUTATION; PLASMID; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VECTOR; SITE DIRECTED MUTAGENESIS; STOMACH CANCER; WESTERN BLOTTING; WILD TYPE; ANIMAL; CHO CELL LINE; CRICETULUS; GENETICS; HAMSTER; METABOLISM; STOMACH TUMOR; STOP CODON; TUMOR CELL LINE; AUTOSOMAL DOMINANT DISORDER; CANCER GENE THERAPY; FAMILIAL CANCER; FEMALE; GENE LOCATION; HEREDITARY DIFFUSE GASTRIC CANCER; IMMUNOFLUORESCENCE; NONVIRAL GENE THERAPY; TREATMENT OUTCOME;

ANIMALS; CADHERINS; CELL LINE, TUMOR; CHO CELLS; CODON, NONSENSE; CRICETINAE; CRICETULUS; HETEROZYGOTE; HUMANS; RNA, TRANSFER; STOMACH NEOPLASMS;

EID: 84906269658     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.292     Document Type: Article

References (50)

1. Fitzgerald RC, Hardwick R, Huntsman D et al: Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010; 47: 436-444.
2. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F: E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. Prog Mol Biol Transl Sci 2013; 116: 337-359.
3. Guilford P, Hopkins J, Harraway J et al: E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
4. Oliveira C, Senz J, Kaurah P et al: Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009; 18: 1545-1555.
5. Masciari S, Larsson N, Senz J et al: Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 2007; 44: 726-731.
6. Corso G, Pedrazzani C, Pinheiro H et al: E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer 2011; 47: 631-639.
7. Kaurah P, MacMillan A, Boyd N et al: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297: 2360-2372.
8. Oliveira C, Seruca R, Carneiro F: Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006; 14: 21-33.
9. Oliveira C, Seruca R, Carneiro F: Hereditary gastric cancer. Best Pract Res Clin Gastroenterol 2009; 23: 147-157.
10. Bordeira-Carrico R, Pego AP, Santos MS, Oliveira C: Cancer syndromes and therapy by stop-codon readthrough. Trends Mol Med 2012; 18: 667-678.
11. Carneiro F, Huntsman DG, Smyrk TC et al: Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004; 203: 681-687.
12. Oliveira C, Sousa S, Pinheiro H et al: Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenter-ology 2009; 136: 2137-2148.
13. Huntsman DG, Carneiro F, Lewis FR: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344: 1904-1909.
14. Oliveira C, Seruca R, Hoogerbrugge N, Ligtenberg M, Carneiro F: Clinical utility gene card for: hereditary diffuse gastric cancer (HDGC). Eur J Hum Genet 2013; 21: doi:10.1038/ejhg.2012.247.
15. Kellermayer R: Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet 2006; 49: 445-450.
16. Welch EM, Barton ER, Zhuo J et al: PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
17. Figueiredo J, Simoes-Correia J, Soderberg O, Suriano G, Seruca R: ADP-ribosylation factor 6 mediates E-cadherin recovery by chemical chaperones. PLoS One 2011; 6: e23188.
18. Mateus AR, Simoes-Correia J, Figueiredo J et al: E-cadherin mutations and cell motility: a genotype-phenotype correlation. Exp Cell Res 2009; 315: 1393-1402.
19. Simoes-Correia J, Figueiredo J, Oliveira C et al: Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. Hum Mol Genet 2008; 17: 3566-3576.
20. Capone JP, Sedivy JM, Sharp PA, RajBhandary UL: Introduction of UAG, UAA, and UGA nonsense mutations at a specific site in the Escherichia coli chloramphenicol acetyltransferase gene: use in measurement of amber, ochre, and opal suppression in mammalian cells. Mol Cell Biol 1986; 6: 3059-3067.
21. Diop D, Chauvin C, Jean-Jean O: Aminoglycosides and other factors promoting stop codon readthrough in human cells. C R Biol 2007; 330: 71-79.
22. Sako Y, Usuki F, Suga H: A novel therapeutic approach for genetic diseases by introduction of suppressor tRNA. Nucleic Acids Symp Ser (Oxf) 2006; 50: 239-240.
23. Temple GF, Dozy AM, Roy KL, Kan YW: Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia. Nature 1982; 296: 537-540.
24. Panchal RG, Wang S, McDermott J, Link CJ Jr: Partial functional correction of xeroderma pigmentosum group a cells by suppressor tRNA. Hum Gene Ther 1999; 10: 2209-2219.
25. Buvoli M, Buvoli A, Leinwand LA: Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. Mol Cell Biol 2000; 20: 3116-3124.
26. Pinheiro H, Carvalho J, Oliveira P et al: Transcription initiation arising from E-cadherin/Cdh1 Intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Hum Mol Genet 2012; 21: 4253-4269.
27. Figueiredo J, Soderberg O, Simoes-Correia J, Grannas K, Suriano G, Seruca R: The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet 2012; 21: 301-309.
28. Pinheiro H, Bordeira-Carrico R, Seixas S et al: Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010; 19: 943-952.
29. Guilford P, Humar B, Blair V: Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010; 13: 1-10.
30. Carvalho J, Pinheiro H, Oliveira C: E-cadherin germline mutations; in Corso G, Roviello F (eds) Spotlight on Familial and Hereditary Gastric Cancer. New York: Springer, 2013; pp 35-49.
31. Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Gronberg H: Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002; 98: 838-843.
32. Dieci G, Fiorino G, Castelnuovo M, Teichmann M, Pagano A: The expanding RNA polymerase III transcriptome. Trends Genet 2007; 23: 614-622.
33. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA: Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013; 39: 60-67.
34. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM: Gastric adenocarci-noma: review and considerations for future directions. Ann Surg 2005; 241: 27-39.
35. Finch A, Evans G, Narod SA: BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond Engl) 2012; 8: 543-555.
36. Floquet C, Deforges J, Rousset JP, Bidou L: Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011; 39: 3350-3362.
37. Zilberberg A, Lahav L, Rosin-Arbesfeld R: Restoration of APC gene function in colorectal cancer cells by aminoglycoside-And macrolide-induced read-through of premature termination codons. Gut 2010; 59: 496-507.
38. Rodriguez EA, Lester HA, Dougherty DA: In vivo incorporation of multiple unnatural amino acids through nonsense and frameshift suppression. Proc Natl Acad Sci USA 2006; 103: 8650-8655.
39. Linde L, Kerem B: Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 2008; 24: 552-563.
40. Phillips-Jones MK, Hill LS, Atkinson J, Martin R: Context effects on misreading and suppression at UAG codons in human cells. Mol Cell Biol 1995; 15: 6593-6600.
41. Keeling KM, Bedwell DM: Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip Rev RNA 2011; 2: 837-852.
42. Dalphin ME, Stockwell PA, Tate WP, Brown CM: Transterm, the translational signal database, extended to include full coding sequences and untranslated regions. Nucleic Acids Res 1999; 27: 293-294.
43. Frischmeyer PA, van Hoof A, O'Donnell K, Guerrerio AL, Parker R, Dietz HC: An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002; 295: 2258-2261.
44. Cao A, Galanello R: Beta-thalassemia. Genet Med 2010; 12: 61-76.
45. Mitui M, Bernatowska E, Pietrucha B et al: ATM gene founder haplotypes and associated mutations in Polish families with ataxia-telangiectasia. Ann Hum Genet 2005; 69: 657-664.
46. Jechlinger W: Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 2006; 5: 803-825.
47. Osborn MJ, McElmurry RT, Lees CJ et al: Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of alpha-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 2011; 19: 450-460.
48. Oliveira H, Fernandez R, Pires LR et al: Targeted gene delivery into peripheral sensorial neurons mediated by self-Assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c. J Control Release 2010; 143: 350-358.
49. Oliveira CR, Rezende CM, Silva MR, Borges OM, Pego AP, Goes AM: Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection. Scien-tificWorldJournal 2012; 2012: 938457.
50. Pires LR, Oliveira H, Barrias CC et al: Imidazole-grafted chitosan-mediated gene delivery: in vitro study on transfection, intracellular trafficking and degradation. Nanomedicine (Lond) 2011; 6: 1499-1512.